Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Faisal A Khokhar

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Human Pathology|September 11, 2009
Angioimmunoblastic T-cell lymphoma in bone marrow: a morphologic and immunophenotypic studyFaisal A Khokhar, William D Payne, Sameer S Talwalkar, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 1, 2012
TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantationKeyur P Patel, Faisal A Khokhar, Tariq Muzzafar, et al.
The Journal of Dermatological Treatment|February 9, 2021
Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension studyLisa A Beck, Diamant Thaçi, Mette Deleuran, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 14, 2009
Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphomaJi Eun Kim, Rajesh R Singh, Jeong Hee Cho-Vega, et al.
Advances in Therapy|November 1, 2022
No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with DupilumabAndrew Blauvelt, Andreas Wollenberg, Lawrence F Eichenfield, et al.
Paediatric Drugs|April 2, 2026
Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic DermatitisAmy S Paller, Andreas Pinter, Lara Wine Lee, et al.
Advances in Therapy|May 19, 2026
Summary of Research: Dupilumab Safety for Treating Infants to Adults with Moderate-to-Severe Atopic DermatitisRichard G Langley, Guy Gherardi, Anna Coleman, et al.
American Journal of Clinical Dermatology|September 24, 2025
The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and AdultsRichard G Langley, Guy Gherardi, Anna Coleman, et al.
Paediatric Drugs|January 24, 2024
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic DermatitisAmy S Paller, Elaine C Siegfried, Michael J Cork, et al.
American Journal of Clinical Dermatology|May 14, 2024
Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension StudyAmy S Paller, Elaine C Siegfried, Eric L Simpson, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Human Pathology|September 11, 2009
Angioimmunoblastic T-cell lymphoma in bone marrow: a morphologic and immunophenotypic studyFaisal A Khokhar, William D Payne, Sameer S Talwalkar, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 1, 2012
TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantationKeyur P Patel, Faisal A Khokhar, Tariq Muzzafar, et al.
The Journal of Dermatological Treatment|February 9, 2021
Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension studyLisa A Beck, Diamant Thaçi, Mette Deleuran, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 14, 2009
Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphomaJi Eun Kim, Rajesh R Singh, Jeong Hee Cho-Vega, et al.
Advances in Therapy|November 1, 2022
No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with DupilumabAndrew Blauvelt, Andreas Wollenberg, Lawrence F Eichenfield, et al.
Paediatric Drugs|April 2, 2026
Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic DermatitisAmy S Paller, Andreas Pinter, Lara Wine Lee, et al.
Advances in Therapy|May 19, 2026
Summary of Research: Dupilumab Safety for Treating Infants to Adults with Moderate-to-Severe Atopic DermatitisRichard G Langley, Guy Gherardi, Anna Coleman, et al.
American Journal of Clinical Dermatology|September 24, 2025
The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and AdultsRichard G Langley, Guy Gherardi, Anna Coleman, et al.
Paediatric Drugs|January 24, 2024
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic DermatitisAmy S Paller, Elaine C Siegfried, Michael J Cork, et al.
American Journal of Clinical Dermatology|May 14, 2024
Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension StudyAmy S Paller, Elaine C Siegfried, Eric L Simpson, et al.
Pageof 4